ArticleCancers2022
Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance.
Vivien Pósa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this papercites it
ArticleCancers2022
Vivien Pósa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.